Compare ELVA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ELVA | CTNM |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.5M | 507.0M |
| IPO Year | 2021 | 2024 |
| Metric | ELVA | CTNM |
|---|---|---|
| Price | $8.49 | $14.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $14.00 | ★ $19.80 |
| AVG Volume (30 Days) | ★ 435.4K | 169.1K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $56.86 | N/A |
| P/E Ratio | $78.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $3.35 |
| 52 Week High | $11.88 | $16.33 |
| Indicator | ELVA | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 53.33 |
| Support Level | $8.11 | $13.86 |
| Resistance Level | $9.12 | $16.17 |
| Average True Range (ATR) | 0.51 | 0.97 |
| MACD | 0.09 | -0.26 |
| Stochastic Oscillator | 94.74 | 51.76 |
Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.